(NewsNation) — Researchers at Stanford Medicine have discovered a naturally occurring molecule that they believe is similar to the active ingredient in the same diabetes drugs that have shown weight loss potential.
BRINP2-related peptide, or BRP, is a naturally occurring molecule that can suppress appetite and promote weight loss in mice and pigs without causing common side effects like nausea, according to the study, which was published in Nature.
The discovery may provide a solution for those who suffer from some of the more severe side effects of Wegovy and Ozempic, which include inflammation of the pancreas, changes in vision, increased risk of thyroid cancer and others.
“The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues,” said assistant professor of pathology Katrin Svensson. “That’s why Ozempic has widespread effects, including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism.”
Ozempic and Wegovy sales have soared in recent years, but shortages and challenges with insurance coverage have made it difficult for many patients to get the drugs.
According to the Centers for Disease Control and Prevention, more than 100 million adults in the U.S. are obese — defined as having a body mass index of 30 or higher — and more than 22 million adults are severely obese, with a BMI of 40 or higher.
